ArticleBlood2022
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature.Cureus · 2026Article
- ALK-positive large B-cell lymphoma presenting in the nasal cavity with CLTC::ALK fusion: a case report of alectinib-integrated therapy followed by autologous hematopoietic stem cell transplantation.Frontiers in oncology · 2026Article
- Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report.Frontiers in oncology · 2026Article
- Rare Case of ALK-Positive Large B-Cell Lymphoma in a Young Adult: Diagnostic and Therapeutic Challenges.Case reports in hematology · 2026Article
- Sequential targeted therapy for anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a case report.Frontiers in medicine · 2026Article
- Comparative DNA Methylation Profiling of Human and Murine ALK-Positive B-Cell Neoplasms.Genes, chromosomes & cancer · 2025Article
- ALK in cancer: from function to therapeutic targeting.Nature reviews. Cancer · 2025Review
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies.Biomedicines · 2024Article
- Article
- Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications.Frontiers in oncology · 2024Review
- Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review.Frontiers in oncology · 2024Article
- Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma Kinase-positive large B-cell lymphoma.Blood advances · 2023Article
- Article
Corrections and comments
- Commented on by
Authors and funding
25 authors at 6 institutions in 1 country.
Jacob D SoumeraiMassachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-3062-6819
Allison RosenthalMayo Clinic, Scottsdale, AZ.
Shannon HarkinsMassachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-7272-9197
Jessica DuffyMassachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-3595-5128
Carmen MeccaBoston Children's Hospital, Boston, MA.ORCID 0000-0002-6770-5094
Yingbing WangMassachusetts General Hospital Cancer Center, Boston, MA.
Ravinder K GrewalMemorial Sloan-Kettering Cancer Center, New York, NY.
Areej R El-JawahriMassachusetts General Hospital Cancer Center, Boston, MA.
Huiyun LiuDana Farber Cancer Institute, Boston, MA.
Cedric MenardMassachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0002-2207-361X
Ahmet DoganMemorial Sloan-Kettering Cancer Center, New York, NY.ORCID 0000-0001-6576-5256
Lei YangDana Farber Cancer Institute, Boston, MA.ORCID 0000-0001-9858-5438
Lisa M RimszaMayo Clinic, Scottsdale, AZ.ORCID 0000-0001-8371-7207
Kurt BantilanMemorial Sloan-Kettering Cancer Center, New York, NY.
Haley MartinMassachusetts General Hospital Cancer Center, Boston, MA.
Matthew LeiMassachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0001-5348-6065
Sydney MohrMassachusetts General Hospital Cancer Center, Boston, MA.
Anna KurilovichBostonGene, Waltham, MA.ORCID 0000-0002-3952-8609
Olga KudryashovaBostonGene, Waltham, MA.ORCID 0000-0003-3320-7764
Ekaterina PostovalovaBostonGene, Waltham, MA.ORCID 0000-0002-3413-3122
Valentina NardiMassachusetts General Hospital Cancer Center, Boston, MA.
Jeremy S AbramsonMassachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0001-8467-9257
Roberto ChiarleBoston Children's Hospital, Boston, MA.ORCID 0000-0003-1564-8531
Andrew D ZelenetzMemorial Sloan-Kettering Cancer Center, New York, NY.ORCID 0000-0003-1403-6883
Abner LouissaintMassachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0001-6707-917X
Massachusetts General Hospital · USMemorial Sloan Kettering Cancer Center · USAddgene · USBoston Children's Hospital · USDana-Farber Cancer Institute · USMayo Clinic in Arizona · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MThe Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7MMechanisms of resistance to ALK inhibitors in ALK-rearranged lymphomaR01CA196703 · NCI · BOSTON CHILDREN'S HOSPITAL · PI CHIARLE, ROBERTO · 2015 to 2025
$4.1MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA021765NCI NIH HHS P50 CA097274NCI NIH HHS R01 CA196703
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lung NeoplasmsLymphoma, B-CellAnaplastic Lymphoma KinaseHumansProtein Kinase InhibitorsAnaplastic Lymphoma KinaseProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.